Blanka Železná Selected Research

Prolactin-Releasing Hormone (Prolactin Releasing Hormone)

1/2022	Palmitoylated prolactin-releasing peptide treatment had neuroprotective but not anti-obesity effect in fa/fa rats with leptin signaling disturbances.
1/2021	Lipidized Prolactin-Releasing Peptide as a New Potential Tool to Treat Obesity and Type 2 Diabetes Mellitus: Preclinical Studies in Rodent Models.
1/2021	Palmitoylated Prolactin-releasing Peptide Reduced Aβ Plaques and Microgliosis in the Cerebellum: APP/PS1 Mice Study.
9/2020	Cellular Signaling and Anti-Apoptotic Effects of Prolactin-Releasing Peptide and Its Analog on SH-SY5Y Cells.
7/2020	Mass spectrometry imaging of free-floating brain sections detects pathological lipid distribution in a mouse model of Alzheimer's-like pathology.
1/2019	Metabolomic Study of Obesity and Its Treatment with Palmitoylated Prolactin-Releasing Peptide Analog in Spontaneously Hypertensive and Normotensive Rats.
1/2018	Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy.
1/2018	Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study.
1/2018	Prolactin-releasing peptide improved leptin hypothalamic signaling in obese mice.
1/2018	Repeated peripheral administration of lipidized prolactin-releasing peptide analog induces c-fos and FosB expression in neurons of dorsomedial hypothalamic nucleus in male C57 mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Blanka Železná Research Topics

Disease

19	Obesity 01/2022 - 09/2014
9	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2016
8	Body Weight (Weight, Body) 01/2022 - 01/2016
6	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 01/2018
5	Insulin Resistance 01/2022 - 09/2014
3	Neuroinflammatory Diseases 01/2022 - 01/2021
2	Glucose Intolerance 01/2022 - 01/2021
2	Gliosis 01/2021 - 01/2019
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 01/2018
2	Amyloid Plaque 07/2020 - 01/2018
2	Cachexia 01/2018 - 03/2012
1	Hypertension (High Blood Pressure) 01/2022
1	Neuroblastoma 09/2020
1	Nervous System Diseases (Neurological Disorders) 09/2020
1	Inflammation (Inflammations) 01/2020
1	Prediabetic State (Prediabetes) 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2019
1	Anorexia 01/2018
1	Tauopathies 01/2018
1	Decapitation 01/2018
1	Chronic Disease (Chronic Diseases) 03/2012

Drug/Important Bio-Agent (IBA)

12	Prolactin-Releasing Hormone (Prolactin Releasing Hormone)IBA 01/2022 - 01/2016
12	palm11-PrRP31IBA 01/2022 - 01/2018
7	LeptinIBA 01/2022 - 01/2016
6	Peptides (Polypeptides)IBA 01/2021 - 01/2016
6	Liraglutide FDA Link 07/2020 - 01/2015
5	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2016
4	Insulin (Novolin)FDA Link 01/2022 - 09/2014
3	tau Proteins (tau Protein)IBA 06/2021 - 09/2014
3	Pharmaceutical PreparationsIBA 01/2021 - 07/2020
3	NeuropeptidesIBA 01/2021 - 01/2016
3	Sodium Glutamate (Accent)IBA 01/2016 - 01/2015
2	LipidsIBA 03/2021 - 07/2020
2	Anti-Obesity Agents (Antiobesity Drugs)IBA 01/2021 - 01/2018
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021 - 01/2016
2	VildagliptinIBA 05/2019 - 01/2016
2	Metformin (Glucophage)FDA LinkGeneric 05/2019 - 01/2016
2	GhrelinIBA 01/2018 - 03/2012
1	Amyloid (Amyloid Fibrils)IBA 01/2021
1	GangliosidesIBA 07/2020
1	Phosphatidylinositols (Phosphatidylinositol)IBA 07/2020
1	AdipokinesIBA 01/2020
1	Hormones (Hormone)IBA 01/2018
1	AcidsIBA 01/2018
1	AntibodiesIBA 01/2018
1	LipopolysaccharidesIBA 01/2018
1	CytokinesIBA 01/2018
1	Ghrelin ReceptorsIBA 01/2018
1	CholesterolIBA 01/2017
1	Nonesterified Fatty Acids (NEFA)IBA 01/2017
1	Triglycerides (Triacylglycerol)IBA 01/2017
1	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2017
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2017
1	prolactin-releasing peptide receptorIBA 01/2016
1	PPAR gammaIBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	EnzymesIBA 01/2016
1	AdiponectinIBA 01/2016
1	Alanine (L-Alanine)FDA Link 01/2016
1	Leptin ReceptorsIBA 01/2016
1	LipopeptidesIBA 01/2015
1	Phosphotransferases (Kinase)IBA 09/2014
1	Glycogen Synthase KinasesIBA 09/2014
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 09/2014

Therapy/Procedure

3	Therapeutics 01/2021 - 01/2016
1	Oral Administration 05/2019
1	Aftercare (After-Treatment) 01/2016